- Raised funding round, Jan 2019
About
TNIK Therapeutics targets cancer stem cell diseases by developing small molecule inhibitors of TNIK, the most downstream transcription regulator of the Wnt pathway, which is a major force driving colorectal carcinogenesis when over-activated. Targeting TNIK regulates the beta catenin-TCF4 transcription complex responsible for the activation of genes important for stemness and proliferation. Moreover, it is a specific activator of the beta-catenin-TCF4 complex in contrast with other transcription regulators that have a pleiotropic effect, suggesting a reduced chance for off-target effects. TNIK Therapeutics obtained an exclusive license from Korea Research Institute of Chemical Technology and Yonsei University Health System in Korea for the development of small molecule inhibitors to TNIK that could help patients with metastatic colon cancer. The company is a portfolio company of FuturX, an Israeli incubator, in partnership with Johnson & Johnson Innovation, Takeda Pharmaceutical Company, and OrbiMed Israel Partners.
Funding history · 1 round · — total
Q&A
- What is TNIK Therapeutics' primary focus?
- TNIK Therapeutics focuses on developing small molecule inhibitors of TNIK to target cancer stem cell diseases, particularly colorectal carcinogenesis.
- When was TNIK Therapeutics founded?
- TNIK Therapeutics was founded in May 2018.
- What is the current status of TNIK Therapeutics?
- TNIK Therapeutics is currently inactive, having ceased operations in August 2022.
- How many employees did TNIK Therapeutics have?
- TNIK Therapeutics had 1-10 employees.
- Which organizations did TNIK Therapeutics obtain an exclusive license from?
- TNIK Therapeutics obtained an exclusive license from Korea Research Institute of Chemical Technology and Yonsei University Health System in Korea.
- Who were the partners in the FuturX incubator program for TNIK Therapeutics?
- TNIK Therapeutics was a portfolio company of FuturX, in partnership with Johnson & Johnson Innovation, Takeda Pharmaceutical Company, and OrbiMed Israel Partners.
- When did TNIK Therapeutics have its last funding round?
- TNIK Therapeutics had a funding round in January 2019.
- Which investor participated in TNIK Therapeutics' January 2019 funding round?
- FutuRx participated in TNIK Therapeutics' January 2019 funding round.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2018-5 |
|---|---|
| Employees (exact) | 2 |
| Status reason | Non Active, Aug 2022 ceased to operate |